Logo image of FRBN

FORBION EUROPEAN ACQUISITI-A (FRBN) Stock Fundamental Analysis

NASDAQ:FRBN - Nasdaq - KYG3619H1020 - Common Stock - Currency: USD

21.695  -0.87 (-3.88%)

After market: 20.14 -1.55 (-7.17%)

Fundamental Rating

1

Taking everything into account, FRBN scores 1 out of 10 in our fundamental rating. FRBN was compared to 0 industry peers in the Unkown industry. Both the profitability and financial health of FRBN have multiple concerns. FRBN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

FRBN had negative earnings in the past year.
In the past year FRBN has reported a negative cash flow from operations.
FRBN Yearly Net Income VS EBIT VS OCF VS FCFFRBN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 0 -500K -1M -1.5M

1.2 Ratios

Industry RankSector Rank
ROA -1.74%
ROE -1.9%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FRBN Yearly ROA, ROE, ROICFRBN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 -0.2 -0.4 -0.6 -0.8 -1

1.3 Margins

FRBN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRBN Yearly Profit, Operating, Gross MarginsFRBN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022

More info and screens

2

2. Health

2.1 Basic Checks

FRBN has about the same amout of shares outstanding than it did 1 year ago.
FRBN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FRBN Yearly Shares OutstandingFRBN Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 5M 10M 15M
FRBN Yearly Total Debt VS Total AssetsFRBN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 17.18 indicates that FRBN is not in any danger for bankruptcy at the moment.
FRBN has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 17.18
ROIC/WACCN/A
WACCN/A
FRBN Yearly LT Debt VS Equity VS FCFFRBN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 0.04 indicates that FRBN may have some problems paying its short term obligations.
A Quick Ratio of 0.04 indicates that FRBN may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
FRBN Yearly Current Assets VS Current LiabilitesFRBN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 500K 1M 1.5M

More info and screens

0

3. Growth

3.1 Past

FRBN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -166.89%.
EPS 1Y (TTM)-166.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-948.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FRBN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FRBN Price Earnings VS Forward Price EarningsFRBN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FRBN Per share dataFRBN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

FRBN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORBION EUROPEAN ACQUISITI-A

NASDAQ:FRBN (10/31/2023, 8:11:12 PM)

After market: 20.14 -1.55 (-7.17%)

21.695

-0.87 (-3.88%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap343.00M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.76
P/tB 2.76
EV/EBITDA N/A
EPS(TTM)-0.15
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS7.87
TBVpS7.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.74%
ROE -1.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z 17.18
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-166.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-948.87%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-573.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.16%
OCF growth 3YN/A
OCF growth 5YN/A